Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Wanbury's 3-Year ROIIC % for the quarter that ended in Mar. 2026 was 269.19%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Wanbury's 3-Year ROIIC % or its related term are showing as below:
BOM:524212's 3-Year ROIIC % is ranked better than 95.66% of 945
companies
in the Drug Manufacturers industry
Industry Median: 3.74
vs BOM:524212: 269.19
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Wanbury 3-Year ROIIC % Related Terms
Wanbury 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Wanbury's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Wanbury's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Wanbury 3-Year ROIIC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Wanbury's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Wanbury's 3-Year ROIIC % falls into.
Wanbury's 3-Year ROIIC % for the quarter that ended in Mar. 2026 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( 2685.455 (Mar. 2026) - 118.604 (Mar. 2023) )
/
( 3947.717 (Mar. 2026) - 2994.169 (Mar. 2023) )
=
2566.851
/
953.548
=
269.19%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Wanbury (BOM:524212) has a 3-Year ROIIC % of 269.19 as of Mar. 2026. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Wanbury and its competitors. According to the industry distribution chart, Wanbury ranks #41 out of 945 companies in the Drug Manufacturers industry, placing it in the top 4.3%.
Is Wanbury's 3-Year ROIIC % too high?
Wanbury's current 3-Year ROIIC % is 269.19. The Drug Manufacturers industry median 3-Year ROIIC % is 3.74. Wanbury's value of 269.19 is 7097.6% above this industry median. Based on the distribution chart, Wanbury ranks #41 out of 945 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Wanbury has a GF Score™ of 66/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Wanbury's 3-Year ROIIC % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Wanbury ranks #41 out of 945 companies for 3-Year ROIIC %. This places Wanbury in the top 4% of its industry — outperforming the majority of peers. The industry median 3-Year ROIIC % is 3.74. Wanbury's value of 269.19 is 7097.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Drug Manufacturers company?
The median 3-Year ROIIC % among Drug Manufacturers companies is 3.74, based on 945 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Wanbury's current 3-Year ROIIC % of 269.19 is 7097.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Wanbury and its competitors. For the Drug Manufacturers industry, the median 3-Year ROIIC % is 3.74 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Wanbury's current 3-Year ROIIC % is 269.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wanbury stock overvalued right now?
Based on GuruFocus' analysis, Wanbury (BOM:524212) is currently considered Fairly Valued. The stock's GF Value™ is ₹250.95, compared to a current price of ₹246.50 — trading 1.8% below its estimated fair value. The current 3-Year ROIIC % is 269.19 and 7097.6% above the Drug Manufacturers industry median of 3.74. Wanbury's overall GF Score™ is 66/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Wanbury (BOM:524212), the current 3-Year ROIIC % is 269.19 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Wanbury (BOM:524212) Overvalued in 2026?
Based on GuruFocus' analysis, Wanbury stock appears to be undervalued.
The current stock price of ₹246.50 is trading 1.8% below its estimated GF Value™ of ₹250.95.
GuruFocus considers Wanbury to be Fairly Valued.
Key valuation signals for BOM:524212:
3-Year ROIIC %: 269.19
GF Value™: ₹250.95 vs. price of ₹246.50 (1.8% below fair value)
Industry Position: 7097.6% above the Drug Manufacturers median (#41 of 945)
No single metric tells the full story. See the BOM:524212 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Wanbury Ltd is engaged in the business of pharmaceutical and related activities, including research. Some of the company's products include Cpink 50mg tablets, Rabiplus capsules, and Folinine softgels, among others. The company has one segment of activity, namely, Pharmaceuticals and related products. It generates revenue from contracts with customers through the sale of manufactured and traded goods. Geographically, key revenue is generated from outside India.
66GF Score
Get the complete analysis for BOM:524212
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524212 has been successfully added to your 
